GUIDE

A Practical Guide to Human Biospecimens: Types, Formats, and Research Applications

Human biospecimens are foundational to modern drug discovery. From early-stage research through translational and clinical development, they provide the most direct way to study human biology, disease mechanisms, and therapeutic response.

But not all biospecimens are created equal.

Understanding the type, format, and intended application of a sample is critical to designing effective studies—and avoiding costly downstream issues.

What Is a Biospecimen?

A biospecimen includes any biological material used for research, such as:

  • Tissue (tumor or normal)
  • Blood and other biofluids
  • Cells (e.g., PBMCs, tumor cells)
  • DNA, RNA, and proteins

These materials may be used immediately in experiments or stored in biorepositories for future research.

Why Specimen Selection Matters

Choosing the wrong specimen format can compromise results—no matter how strong the study design.

The right selection impacts:

  • Data quality and reproducibility
  • Assay compatibility
  • Biomarker discovery success
  • Translational relevance

In short: specimen strategy is experimental strategy.

Tissue Specimens: Formats and Use Cases

FFPE (Formalin-Fixed, Paraffin-Embedded)

Best for: Histology, IHC, FISH, and many clinical assays

  • Standard format for pathology and diagnosis
  • Suitable for mutation analysis and biomarker studies
  • Long-term storage, but nucleic acid quality can degrade over time

Key considerations:

  • Block age (ideally <3–5 years for molecular work)
  • Tumor content (typically >30–50%)
  • Necrosis levels

Snap-Frozen (Flash-Frozen)

Best for: DNA, RNA, and protein analysis

  • Preserves molecular integrity better than FFPE
  • Enables high-quality genomic and proteomic studies

Trade-off:

  • Limited visibility into tumor composition unless paired with mirrored FFPE

Fresh Tissue

Best for: Functional assays and microenvironment studies

  • Preserves tumor architecture and immune context
  • Used in immuno-oncology and biomarker discovery
  • Supports PDX model development

Constraint: Short viability window and complex logistics

Viably Preserved Tissue

Best for: Extended functional studies

  • Maintains cell viability with specialized processing
  • Bridges the gap between fresh tissue and cryopreserved formats

Dissociated Tumor Cells (DTCs)

Best for: Cell-based assays and scalable studies

  • Generated via enzymatic/mechanical dissociation
  • Suitable for FACS, single-cell genomics, and screening

Trade-off: Loss of native tumor architecture

Biofluids: Flexible and Scalable Options

Whole Blood (Fresh)

Applications: PBMC isolation, immunoprofiling, cell culture

Frozen Whole Blood

Applications: DNA and RNA extraction

Plasma

Applications:

  • ctDNA / ctRNA
  • miRNA and exosome analysis
  • Liquid biopsy workflows

Serum

Applications:

  • Tumor marker analysis (e.g., CEA, CA125)
  • Proteomics and biomarker discovery
  • Autoimmune disease research

Bone Marrow Aspirates

Applications: Hematologic studies and molecular analysis

Cell-Based Specimens

PBMCs (Peripheral Blood Mononuclear Cells)

  • Widely used in immunology and cell-based assays
  • Support genomics, proteomics, and functional studies

BMMCs (Bone Marrow Mononuclear Cells)

  • Critical for hematology and oncology research

Dissociated Tumor Cells

  • Enable single-cell analysis and immune profiling

Nucleic Acids and Derived Materials

DNA & RNA

Applications:

  • Next-generation sequencing (NGS)
  • RT-PCR
  • Transcriptomics and gene expression studies

Protein Lysates

  • Western blotting
  • Proteomics
  • Immunoprecipitation

Downstream Applications: Where Biospecimens Deliver Value

Human biospecimens support a wide range of research applications:

  • Disease mechanism studies
  • Drug safety and efficacy testing
  • Biomarker discovery and validation
  • Diagnostic development
  • Personalized medicine approaches

They also provide a more clinically relevant model than synthetic systems or animal models.

Choosing the Right Biospecimen Strategy

Selecting a biospecimen provider—and the right format—requires careful evaluation.

Key considerations:

  • Quality and consistency of samples
  • Ethical sourcing and regulatory compliance
  • Processing and handling protocols
  • Availability of matched samples and metadata
  • Ability to support custom collection protocols

A strong partner should not just supply samples—but help align specimen strategy with study goals.

How ABS Bio Supports Researchers

ABS Bio works with biopharma and research teams to deliver fit-for-purpose biospecimens aligned with study design.

Our capabilities include:

  • Broad access to tissue, biofluid, and cell-based specimens
  • Standardized, quality-controlled procurement and processing
  • Support for custom protocols and complex study requirements
  • Reliable logistics and consistent sample delivery

By combining quality, flexibility, and operational discipline, ABS Bio helps researchers reduce variability and improve study outcomes.

Conclusion

Human biospecimens are among the most powerful tools in biomedical research—but only when used correctly.

Understanding specimen types, formats, and applications is essential to designing effective studies and generating meaningful data.

With the right strategy—and the right partner—biospecimens can accelerate discovery, improve translational success, and ultimately bring better therapies to patients.

VLADISLAV GOLUBKOV, PH.D.

Research & Business Development Director, ABS Bio

30+ years in life sciences

Biotechnology expert

45+ peer-reviewed publications

Vladislav Golubkov, Ph.D., is Research & Business Development Director at ABS Bio. He is a biotechnology expert with over 30 years of industry and academic experience in biospecimen solutions, biobanking, cell and molecular biology, and translational research. Dr. Golubkov specializes in the commercialization of custom biospecimen and research services, partnering with pharmaceutical and biotechnology companies to deliver high-quality, fit-for-purpose solutions for drug discovery and clinical development across diverse therapeutic areas. He has extensive experience aligning scientific operations with client and market needs to drive revenue growth and long-term partnerships.

Prior to his current role, Dr. Golubkov held scientific and leadership positions at the University of Southern California (USC), Sanford Burnham Prebys Medical Discovery Institute, and Cureline Inc.

He is a published author of over 45 peer-reviewed articles and a former NIH-funded principal investigator.